Resources

Informative Videos

Both videos are great Harvard** videos that discuss how GLP-1 and GIR work as well as side effects and other information. Tirzepatide is now FDA approved, but at the time of the recording of these videos, Tirzepatide was still pending FDA approval.

https://youtu.be/P6gt4A_3Whs

https://youtu.be/DYuy6hDPat0

Lilly's tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks | Eli Lilly and Company

 

 

Disclaimer

*Mounjaro™ and Zepbound™ are exclusively available from Eli Lilly and Company™. Healthspan does not claim any affiliation with, or endorsement from the above mentioned products or entities.

**Harvard Medical School Continuing Education is in no way affiliated with and does not provide any endorsement to Healthspan. The videos linked are for educational purposes only.

***C. S. Mott Children’s Hospital Michigan Medicine is in no way affiliated with and does not provide any endorsement to Healthspan. The PDF provided is for educational purposes only.